OncLive TV

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses the safety profile of daraxonrasib in patients with KRAS-mutated pancreatic ductal adenocarcinoma

Alberto Chiappori, MD, discusses the selection between frontline treatment options, including ensartinib, in ALK-positive non–small cell lung cancer.

Megan Melody, MD, discusses the importance of female mentorship on her career development as a hematologist/oncologist.

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

Marco Ruella, MD, discusses ways to develop accessible cancer treatments to more greatly benefit diverse populations of patients with multiple myeloma.

Matthew Cortese, MD, MPH, discusses the benefit of analyzing multiple biological layers when identifying immunologic changes in CLL after venetoclax.

Paul G. Richardson, MD, discusses the role of triplet regimens as the current standard of care in newly diagnosed multiple myeloma.

Aditya Bardia, MD, MPH, FASCO, discusses the need for widespread HER2 testing in patients with HER2-low and -ultralow metastatic breast cancer.

Marwan G. Fakih, MD, emphasizes the need for next-generation sequencing in colorectal cancer to inform treatment sequencing.

Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.

Icro Meattini, ​MD, discusses the benefits of adjuvant radiation therapy vs endocrine therapy in patients with luminal-like early breast cancer.

Nataliya Uboha, MD, PhD, discusses how the FDA approval of tislelizumab plus chemotherapy​ addresses unmet needs for patients with metastatic ESCC.

Reshma Jagsi, MD, Dphil, discusses factors that could influence the omission of radiation therapy following breast-conserving surgery in early-stage breast cancer.

Patrick I. Borgen, MD, discusses the need for improved risk stratification in early-stage breast cancer.

Emily M. Hinchcliff, MD, MPH, discusses the growing role of ADCs like mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

Pooja Phull, MD, discusses the rationale for assessing CAR T-cell therapy in the real-world vs trial setting in relapsed/refractory multiple myeloma.

William D. Tap, MD, discusses the FDA approval of vimseltinib for patients with symptomatic TGCT and this agent's role in the treatment paradigm.

Sairah Ahmed, MD, discusses treatment challenges for patients with relapsed/refractory large B-cell lymphoma following CAR T-cell therapy.

Regina Barragan-Carrillo, MD, discusses findings from an analysis of global RCC clinical trial availability in high- vs low-to-middle–income countries.

Yasmin Abaza, MD, discusses how the ongoing investigation of emavusertib could address the need for more targeted therapies in AML and MDS.

Alfred Garfall, MD, discusses the potential role of CAR T-cell therapy in multiple myeloma either as consolidation or maintenance in the up-front setting.

Matthew Wagar, MD, discusses lenvatinib plus pembrolizumab vs chemotherapy as first-line treatment for advanced endometrial cancer.

Koral Shah, MD, details the rationale of evaluating worldwide disparities in bladder cancer clinical trial availability.

Nikolai Podoltsev, MD, PhD, discusses the addition of blinatumomab to consolidation chemotherapy in older patients with newly diagnosed BCR-ABL1–negative ALL.

Jin-Ji Yang, MD, discusses osimertinib plus savolitinib as a first-line treatment in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC.

Kanwal P.S. Raghav, MBBS, MD, details the preliminary safety of a ABBV-400 regimen for the treatment of patients with previously treated mCRC.

Richard T. Lee, MD, discusses research showing the benefits of acupuncture, ginger, and ginseng for improving symptoms in patients with GI cancers.

Evangelia Vlachou, MD, discusses response rates with enfortumab vedotin alone or with pembrolizumab in patients with upper tract urothelial cancer.

Caicun Zhou, MD, PhD, discusses data for ivonescimab vs pembrolizumab as first-line treatment for patients with PD-L1–positive advanced NSCLC.